Insmed(US:INSM) The Motley Fool·2025-11-30 08:14Core Insights - Stanley Druckenmiller, a renowned investor, has a significant focus on biotech stocks, which make up 30% of his portfolio despite the popularity of AI stocks in the market [2][3]. Biotech Sector Overview - The biotech sector is challenging for retail investors due to its speculative nature and the need for scientific knowledge [2]. - Druckenmiller's private investment firm, Duquesne Family Office, has three major biotech holdings: Natera, Insmed, and Teva Pharmaceutical [3]. Natera - Natera represents 13% of Duquesne's portfolio, with over 3.2 million shares valued at approximately $517 million [4]. - The company utilizes AI to enhance disease detection, focusing on women's health, oncology, and organ health [5]. - Natera's stock has increased by 48% in 2023, with a 35% revenue growth year-over-year for the first nine months of 2025 [6]. - The company raised its annual revenue guidance for 2025 by $160 million, although it faces increased losses due to R&D and administrative expenses [6]. Insmed - Insmed accounts for 8.6% of the portfolio, with over 2.4 million shares valued at around $349 million [7]. - The company is focused on developing drugs for chronic diseases, with two drugs currently commercialized [8]. - Insmed's stock has surged nearly 200% year-to-date, driven by a 21% revenue growth from its drug Arikayce and the FDA approval of Brinsupri [9]. Teva Pharmaceutical - Teva Pharmaceutical comprises 8.3% of the portfolio, with approximately 16.6 million shares valued at about $335.2 million [10]. - The company manufactures a variety of drugs and has seen its stock rise over 17% this year [11]. - Teva reported a 3% year-over-year revenue growth to nearly $4.5 billion in the third quarter and has a strong pipeline of drugs nearing commercialization [12]. - The stock is trading at 1.7 times forward revenue and 9.5 times forward earnings, indicating a reasonable valuation [13].